Compare WSO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | GH |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 13.3B |
| IPO Year | N/A | 2018 |
| Metric | WSO | GH |
|---|---|---|
| Price | $400.95 | $92.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $418.33 | $117.80 |
| AVG Volume (30 Days) | 383.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $5.49 | $29.73 |
| Revenue Next Year | $5.79 | $27.71 |
| P/E Ratio | $34.24 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $323.05 | $34.91 |
| 52 Week High | $533.07 | $120.74 |
| Indicator | WSO | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 36.16 |
| Support Level | $400.37 | $90.44 |
| Resistance Level | $430.44 | $103.16 |
| Average True Range (ATR) | 14.20 | 5.67 |
| MACD | -3.12 | -0.91 |
| Stochastic Oscillator | 18.50 | 16.70 |
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.